National Strategy For Biomedical Innovation Simmering On Hamburg’s Agenda
This article was originally published in The Pink Sheet Daily
FDA commissioner says all stakeholders need to come to the table to develop a path for maintaining U.S. preeminence in making medical discoveries and moving them through the pharmaceutical pipeline into patients’ hands.
You may also be interested in...
Presidential advisory panel makes eight recommendations to improve innovation in drug discovery, development and evaluation; calls for broad partnership of stakeholders to accelerate therapeutics, $40 million annual appropriations for FDA’s Sentinel System.
Sweden’s government has allocated 4 billion kroner for the R&D sector and SEK 600 million specifically for life science in the hopes of rejuvenating Swedish R&D and getting the nation back on the top rankings of medicine innovation. It’s a theme being heard in other European countries.
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.